Literature DB >> 16029448

Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3.

Ken I Mills1, Amanda F Gilkes, Val Walsh, Marion Sweeney, Rosemary Gale.   

Abstract

Mutations of the FLT3 gene, a receptor tyrosine kinase, are the most frequent genetic alteration reported in acute myeloid leukaemia, with internal tandem duplications (ITD) or mutations within the activating loop (AL) reported at a frequency of around 24% and 6%, respectively. ITD mutations have associated with a poor prognosis. In this study we have used polymerase chain reaction (PCR), combined with restriction enzyme digestion for the detection of AL mutations, with the DNA products separated on the Agilent 2100 Bioanalyser using a DNA-500 kit. This analysis enabled the rapid identification of mutations in FLT3, approximate sizing of the ITD, an estimate of the proportion of mutant RNA and in some cases, specific heteroduplex patterns associated with triplet deletions. Our data shows that approximately 16% of the patients examined had an ITD mutation and over 13% had a mutation in the AL including triplet deletions involving codons 835/836 and point mutations in codon D839. Based on the sensitivity and speed of the bioanalyser, we suggest that this method is invaluable and provides an improvement to the current use of agarose gels for the analysis of FLT3 PCR products.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16029448     DOI: 10.1111/j.1365-2141.2005.05589.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  Clinical implications of gene expression profiling of acute myeloid leukemia.

Authors:  Kenneth I Mills; Amanda F Gilkes
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

2.  Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.

Authors:  Daniel J DeAngelo; Richard M Stone; Mark L Heaney; Stephen D Nimer; Ronald L Paquette; Rebecca B Klisovic; Michael A Caligiuri; Michael R Cooper; Jean-Michel Lecerf; Michael D Karol; Shihong Sheng; Nick Holford; Peter T Curtin; Brian J Druker; Michael C Heinrich
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

3.  Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.

Authors:  Hanna Janke; Friederike Pastore; Daniela Schumacher; Tobias Herold; Karl-Peter Hopfner; Stephanie Schneider; Wolfgang E Berdel; Thomas Büchner; Bernhard J Woermann; Marion Subklewe; Stefan K Bohlander; Wolfgang Hiddemann; Karsten Spiekermann; Harald Polzer
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 4.  Molecular testing for acute myeloid leukemia.

Authors:  Dahui Qin
Journal:  Cancer Biol Med       Date:  2021-08-04       Impact factor: 4.248

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.